Your session is about to expire
← Back to Search
Abemaciclib + Ramucirumab for Esophageal Cancer
Study Summary
This trial suggests that CDK4/6 inhibitors could be a successful treatment for esophageal and gastroesophageal junction tumors, which are often resistant to chemotherapy and immunotherapy.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2018 Phase 2 trial • 132 Patients • NCT02102490Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My cancer is a type called squamous cell carcinoma.I can provide a sample of my tumor for study.My cancer is in the esophagus or where the stomach meets the esophagus, and it's an adenocarcinoma.I've had treatment for advanced cancer and if HER2 positive, received an anti-HER2 drug.My cancer has a small cell component.I am fully active or can carry out light work.
- Group 1: Abemaciclib plus Ramucirumab
- Approved for 5 Other Conditions - This treatment demonstrated efficacy for 5 other conditions.
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there any existing investigations that have explored the efficacy of Abemaciclib?
"Presently, there are 139 Abemaciclib experiments in process. Of these trials, 24 have reached Phase 3. Across the world 8500 locations offer clinical testing of this drug with two major hubs based in Alicante and Pamplona/Iruña respectively."
What is the current number of participants contributing to this clinical experiment?
"Unfortunately, this medical trial is not presently recruiting patients. First posted on June 1st 2021, the study has since been updated four days later; however, individuals seeking other trials may be interested to know that there are 768 adenocarcinoma studies and 139 Abemaciclib investigations which are actively enrolling participants."
Are enrollees still being recruited for this investigation?
"According to clinicaltrials.gov, this medical trial is not actively seeking participants at present; the listing was initially posted on June 1st 2021 and last updated on June 4th 2021. Despite its inactivity, there are 907 other trials that are currently recruiting patients for their studies."
Is this experimental trial a pioneering endeavor?
"Abemaciclib has been the subject of scientific inquiry since 2009, when Eli Lilly and Company sponsored its first trial involving 220 participants. After receiving Phase 1 drug approval, 139 active trials for Abemaciclib have sprung up across 43 countries and 1584 cities."
How has Abemaciclib been employed to treat certain medical conditions?
"Abemaciclib is the go-to therapy for treating non-small cell lung carcinoma, as well as conditions such as metastatic disease and adenocarcinoma with a high risk of relapse."
Share this study with friends
Copy Link
Messenger